Moderna
MRNA
#275
Rank
A$125.82 B
Marketcap
A$315.15
Share price
-0.47%
Change (1 day)
661.11%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.

Moderna (MRNA) - Total debt

Total debt on the balance sheet as of June 2026 : A$1.82 Billion

According to Moderna 's latest financial reports the company's total debt is A$1.82 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Moderna - Total debt on balance sheet (from 2017 to 2026)

Total debt by year

Year Total debt Change
2025-12-31A$1.94 B62.23%
2024-12-31A$1.20 B-34.17%
2023-12-31A$1.82 B3.46%
2022-12-31A$1.76 B39.57%
2021-12-31A$1.26 B309.93%
2020-12-31A$0.30 B63.03%
2019-12-31A$0.18 B297.69%
2018-12-31A$47.53 M136.58%
2017-12-31A$20.09 M15.87%
2016-12-31A$17.34 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Johnson & Johnson
JNJ
A$69.69 B 3,710.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
A$69.66 B 3,708.39%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Merck
MRK
A$76.62 B 4,088.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A$1.99 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A$26.4 M-98.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
A$1.80 B-1.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Arrowhead Pharmaceuticals
ARWR
A$1.39 B-23.57%๐Ÿ‡บ๐Ÿ‡ธ USA